Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Recurrent Mediastinal Lymphoma Clear all

Recruiting Phase 2 Interventional

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

NCT06784726

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration, Biopsy Procedure; Biological · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated May 5, 2026 · Synced May 22, 2026, 12:54 AM EDT

Active, not recruiting Phase 2 Interventional

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

NCT05202782

View directory record Official record

Conditions: Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions: Chimeric Antigen Receptor T-Cell Therapy, Quality-of-Life Assessment, Questionnaire Administration, Zanubrutinib; Biological · Other · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 2
States / cities: Chicago, Illinois • Milwaukee, Wisconsin

Source: ClinicalTrials.gov public record

Updated Oct 15, 2024 · Synced May 22, 2026, 12:54 AM EDT

Completed Not applicable Interventional

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167

View directory record Official record

Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Interventions: Adaptive Bridging Radiation Therapy (ABRT); Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Dec 8, 2025 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 2 Interventional Results available

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT03210662

View directory record Official record

Conditions: Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: External Beam Radiation Therapy, Pembrolizumab; Radiation · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 12, 2026 · Synced May 22, 2026, 12:54 AM EDT

Not listed No phase listed Observational

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

NCT04870853

View directory record Official record

Conditions: Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Electronic Health Record Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Nov 13, 2023 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 2 Interventional Results available

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

NCT03484819

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
Interventions: Copanlisib Hydrochloride, Nivolumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 15
States / cities: Birmingham, Alabama • Iowa City, Iowa • Hays, Kansas + 12 more

Source: ClinicalTrials.gov public record

Updated Mar 2, 2025 · Synced May 22, 2026, 12:54 AM EDT

Terminated Phase 2 Interventional

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05972720

View directory record Official record

Conditions: Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Interventions: Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug); Drug
Lead sponsor: CARGO Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Little Rock, Arkansas • Duarte, California • Los Angeles, California + 24 more

Source: ClinicalTrials.gov public record

Updated May 14, 2025 · Synced May 22, 2026, 12:54 AM EDT

Active, not recruiting Phase 2 Interventional Results available

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

View directory record Official record

Conditions: ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions: Nivolumab, Varlilumab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older

Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more

Source: ClinicalTrials.gov public record

Updated May 11, 2026 · Synced May 22, 2026, 12:54 AM EDT

Recruiting Phase 1 Interventional

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

NCT06209619

View directory record Official record

Conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent, High Grade B-Cell Lymphoma-Recurrent, Primary Mediastinal Large B-Cell Lymphoma-Recurrent, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory, Diffuse Large B-Cell Lymphoma-Refractory, Follicular Lymphoma-Refractory, High Grade B-Cell Lymphoma-Refractory, Primary Mediastinal Large B-Cell Lymphoma-Refractory, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography, Rituximab; Procedure · Drug · Biological
Lead sponsor: Nathan Denlinger; Other
Eligibility: 18 Years and older

Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Feb 26, 2026 · Synced May 22, 2026, 12:54 AM EDT

Active, not recruiting Phase 2 Interventional

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05507541

View directory record Official record

Conditions: Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory ALK Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Gray Zone Lymphoma
Interventions: Biospecimen Collection, Computed Tomography, Ontorpacept, Pembrolizumab, Positron Emission Tomography, Maplirpacept, Biopsy; Procedure · Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Iowa City, Iowa • Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated Apr 21, 2026 · Synced May 22, 2026, 12:54 AM EDT

Recruiting Phase 1 Interventional

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

NCT05077527

View directory record Official record

Conditions: AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Duarte, California • Chicago, Illinois • New York, New York + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

NCT03035331

View directory record Official record

Conditions: Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions: Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment; Procedure · Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 2 Interventional Results available

CT-011 MAb in DLBCL Patients Following ASCT

NCT00532259

View directory record Official record

Conditions: Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
Interventions: CT-011; Drug
Lead sponsor: CureTech Ltd; Industry
Eligibility: 18 Years and older

Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more

Source: ClinicalTrials.gov public record

Updated Sep 11, 2014 · Synced May 22, 2026, 12:54 AM EDT

Recruiting Phase 2 Interventional

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT05672251

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab, Positron Emission Tomography; Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Duarte, California

Source: ClinicalTrials.gov public record

Updated May 10, 2026 · Synced May 22, 2026, 12:54 AM EDT

Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)

NCT06504394

View directory record Official record

Conditions: Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent, Primary Mediastinal Large B-cell Lymphoma Refractory
Interventions: Pembrolizumab (+) Berahyaluronidase alfa; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older

Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Iowa City, Iowa • Waukee, Iowa • Las Vegas, Nevada + 1 more

Source: ClinicalTrials.gov public record

Updated Feb 8, 2026 · Synced May 22, 2026, 12:54 AM EDT

Completed Phase 2 Interventional Results available

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

NCT04432506

View directory record Official record

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jan 27, 2025 · Synced May 22, 2026, 12:54 AM EDT

Recruiting Phase 1Phase 2 Interventional

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

NCT06536049

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Ibrutinib, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Yazeed Sawalha; Other
Eligibility: 18 Years and older

Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Columbus, Ohio

Source: ClinicalTrials.gov public record

Updated Feb 18, 2026 · Synced May 22, 2026, 12:54 AM EDT

Completed No phase listed Observational

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

NCT04409314

View directory record Official record

Conditions: Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Malignant Neoplasm, Recurrent Plasma Cell Myeloma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Malignant Neoplasm, Refractory Plasma Cell Myeloma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Interventions: Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography; Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Source: ClinicalTrials.gov public record

Updated Aug 20, 2023 · Synced May 22, 2026, 12:54 AM EDT

Active, not recruiting Phase 1 Interventional

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

NCT05359211

View directory record Official record

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Lisocabtagene Maraleucel, Polymer-conjugated IL-15 Receptor Agonist NKTR-255, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Lumbar Puncture, Computed Tomography, Positron Emission Tomography, Biospecimen Collection, Biopsy; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older

Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Mar 19, 2026 · Synced May 22, 2026, 12:54 AM EDT

Recruiting Phase 2 Interventional

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373

View directory record Official record

Conditions: Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older

Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more

Source: ClinicalTrials.gov public record

Updated Jan 27, 2026 · Synced May 22, 2026, 12:54 AM EDT